3SBio Inc. (1530.HK)
HKD 6.11
(-0.49%)
HKD 6.11
(-0.49%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.11 Billion CNY | 7.94% |
| 2022 | 6.58 Billion CNY | 44.64% |
| 2021 | 4.55 Billion CNY | -0.66% |
| 2020 | 4.58 Billion CNY | 3.03% |
| 2019 | 4.44 Billion CNY | -9.78% |
| 2018 | 4.93 Billion CNY | -19.45% |
| 2017 | 6.12 Billion CNY | 43.32% |
| 2016 | 4.27 Billion CNY | 329.41% |
| 2015 | 994.96 Million CNY | -26.99% |
| 2014 | 1.36 Billion CNY | 1422.04% |
| 2013 | 89.54 Million CNY | 6.02% |
| 2012 | 84.45 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 7.07 Billion CNY | 0.0% |
| 2024 Q1 | 7.07 Billion CNY | -0.58% |
| 2023 Q1 | 7.2 Billion CNY | 9.37% |
| 2023 FY | 7.11 Billion CNY | 7.94% |
| 2023 Q4 | 7.11 Billion CNY | 0.0% |
| 2023 Q3 | 7.11 Billion CNY | -1.31% |
| 2023 Q2 | 7.2 Billion CNY | 0.0% |
| 2022 Q4 | 6.58 Billion CNY | -0.86% |
| 2022 FY | 6.58 Billion CNY | 44.64% |
| 2022 Q1 | 6.09 Billion CNY | 33.91% |
| 2022 Q2 | 6.09 Billion CNY | 0.0% |
| 2022 Q3 | 6.64 Billion CNY | 8.95% |
| 2021 FY | 4.55 Billion CNY | -0.66% |
| 2021 Q2 | 4.41 Billion CNY | 0.0% |
| 2021 Q1 | 4.41 Billion CNY | -3.76% |
| 2021 Q3 | 4.55 Billion CNY | 3.22% |
| 2021 Q4 | 4.55 Billion CNY | 0.0% |
| 2020 Q1 | 6.1 Billion CNY | 37.29% |
| 2020 Q2 | 6.1 Billion CNY | 0.0% |
| 2020 Q3 | 4.58 Billion CNY | -24.95% |
| 2020 Q4 | 4.58 Billion CNY | 0.0% |
| 2020 FY | 4.58 Billion CNY | 3.03% |
| 2019 FY | 4.44 Billion CNY | -9.78% |
| 2019 Q1 | 5.34 Billion CNY | 8.37% |
| 2019 Q4 | 4.44 Billion CNY | 0.0% |
| 2019 Q3 | 4.44 Billion CNY | -16.75% |
| 2019 Q2 | 5.34 Billion CNY | 0.0% |
| 2018 Q1 | 5.53 Billion CNY | -9.58% |
| 2018 Q4 | 4.93 Billion CNY | 0.0% |
| 2018 Q3 | 4.93 Billion CNY | -10.92% |
| 2018 Q2 | 5.53 Billion CNY | 0.0% |
| 2018 FY | 4.93 Billion CNY | -19.45% |
| 2017 Q2 | 3.64 Billion CNY | 0.0% |
| 2017 Q3 | 6.12 Billion CNY | 67.9% |
| 2017 Q4 | 6.12 Billion CNY | 0.0% |
| 2017 FY | 6.12 Billion CNY | 43.32% |
| 2017 Q1 | 3.64 Billion CNY | -14.64% |
| 2016 Q1 | 4.74 Billion CNY | 376.78% |
| 2016 FY | 4.27 Billion CNY | 329.41% |
| 2016 Q4 | 4.27 Billion CNY | 0.0% |
| 2016 Q3 | 4.27 Billion CNY | -9.94% |
| 2016 Q2 | 4.74 Billion CNY | 0.0% |
| 2015 Q3 | 772.61 Million CNY | -32.94% |
| 2015 Q2 | 1.15 Billion CNY | 9.55% |
| 2015 Q1 | 1.05 Billion CNY | -22.82% |
| 2015 FY | 994.96 Million CNY | -26.99% |
| 2015 Q4 | 994.96 Million CNY | 28.78% |
| 2014 FY | 1.36 Billion CNY | 1422.04% |
| 2014 Q4 | 1.36 Billion CNY | 0.0% |
| 2014 Q1 | - CNY | -100.0% |
| 2013 FY | 89.54 Million CNY | 6.02% |
| 2013 Q4 | 89.54 Million CNY | 0.0% |
| 2012 Q4 | 78.8 Million CNY | 16.52% |
| 2012 FY | 84.45 Million CNY | 0.0% |
| 2012 Q3 | 67.62 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | -4553.528% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | -0.755% |